- Pfizer shares gained nearly 3% in premarket trading Monday.
- BioNTech's US shares surged as much as 11% in premarket trading Monday.
- Watch Pfizer and BioNTech trade live on Markets Insider.
- Read more on Business Insider.
ADVERTISEMENT
Pfizer and BioNTech shares rise after FDA grants 2 coronavirus vaccines 'fast track' status (PFE, BNTX)
Two experimental coronavirus vaccines developed by Pfizer and BioNTech received Fast Track status from the US Food and Drug Administration, the companies announced Monday .
ADVERTISEMENT
Two experimental coronavirus vaccines developed jointly by Pfizer and BioNTech have received Fast Track status from the US Food and Drug Administration, the companies announced Monday.
Shares of Pfizer rose as much as 3% in premarket trading Monday. BioNTech's US-listed shares surged more than 11% at the same time.
The candidates that received Fast Track status, BNT162b1 and BNT162b2, are the most advanced of four potential vaccines being developed by the German biotech company and the US pharmaceutical giant.
ADVERTISEMENT
Both are being assessed in ongoing trials in the US and Germany.In early July, BNT162b1 showed positive early results in a human trial in the US. Early data from the German trial of BNT162b1 are expected to be released in July, the company said.
Pfizer and BioNTech expect to start another large trial with up to 30,000 participants later this month, subject to regulatory approval.
If the ongoing studies are successful, and the vaccine candidate receives regulatory approval, the companies said they expect to manufacture up to 100 million doses by the end of the year and potentially more than 1.2 billion doses by the end of 2021.
The FDA's Fast Track process is designed to speed the development and review of drugs and vaccines that "are intended to treat or prevent serious conditions that have the potential to address an unmet medical need," according to a statement.
ADVERTISEMENT
Pfizer has shed nearly 14% year-to-date, while BioNTech shares have skyrocketed 107%.
NOW WATCH: Pathologists debunk 13 coronavirus myths
See Also:
- 'A big mistake': Kudlow says another shutdown to curb surging coronavirus cases could threaten a V-shaped economic recovery
- A gauge of US service activity posts is biggest monthly jump since 1997 as the economy reopens
- A gauge of US consumer comfort falls for the first time in 7 weeks as coronavirus cases climb
FOLLOW BUSINESS INSIDER AFRICA
ADVERTISEMENT
Recommended articles
Full list: Banking transactions exempted from CBN’s cybersecurity levy
Edward Howarth of DashTickets talks about gambling in Africa
Eco-friendly gambling: The impact of online slots on sustainability
Chad to become the first of Africa's current junta-led states to move to democracy
Russia spreads its military influence to another African country
A look into South Korea’s rice gift to Africa
FBNBank Ghana changes to FirstBank Ghana to align with group identity
Nigeria restricts power export to neighbouring countries to meet domestic demand